Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers(†)

BACKGROUND: Patients with EGFR-mutant lung cancers treated with EGFR tyrosine kinase inhibitors (TKIs) develop clinical resistance, most commonly with acquisition of EGFR T790M. Evolutionary modeling suggests that a schedule of twice weekly pulse and daily low-dose erlotinib may delay emergence of E...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Oncol
Main Authors: Yu, H. A., Sima, C., Feldman, D., Liu, L. L., Vaitheesvaran, B., Cross, J., Rudin, C. M., Kris, M. G., Pao, W., Michor, F., Riely, G. J.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5834093/
https://ncbi.nlm.nih.gov/pubmed/28073786
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdw556
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados